PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.
User's hair loss journey includes Minoxidil 5%, HIM's topical finasteride and minoxidil, derma rolling, and rosemary oil. Experiences some side effects, still considering hair transplant for better hairline.
OP injured their temple using derma rolling and tretinoin, causing peeling and potential hair follicle damage. Users suggest the injury might be permanent, possibly resulting in scar tissue where hair won't grow.
The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.
Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.
The conversation discusses the high cost of CB-03-01, a topical antiandrogen for hair loss, which is considered safe and remains localized upon application. It questions whether the expense is justified compared to the lower risks it poses relative to finasteride.
Switching from finasteride to dutasteride can worsen hair loss for some men due to increased testosterone levels. Topical treatments like RU58841 and Pyrilutamide are suggested to counteract these effects, but individual responses vary.
A user is interested in creating a hair growth serum using oleic acid, palmitoleic acid, and anhydrous ethanol, and seeks advice on sourcing these ingredients. Another user plans to mix these with minoxidil, which already contains ethanol, and mentions using RU58841.
The post and conversation are about the high cost and skepticism surrounding pyrilutamide as a hair loss treatment, with comparisons to minoxidil, finasteride, and RU58841. The original poster defends pyrilutamide's effectiveness and criticizes others for dismissing it without proper understanding.
The conversation is about a person who started using finasteride, minoxidil, and a dermaroller for hair loss in September 2023 and has seen significant improvement after 3 and a half months. Other users are expressing happiness and support for the progress made.
The conversation is about experiences with Dutasteride Mesotherapy and its symptoms compared to oral dutasteride. Users discuss the effectiveness and side effects of this treatment for hair loss.
A user shared their experience with wearing a hair system for a year after finasteride affected their libido. They stopped using the hair system and are open to questions about the experience.
The conclusion of the conversation is that dying the hair can be an effective method for managing hair loss, particularly for those with diffuse thinning.
A user shared their experience using topical finasteride for 6 months, showing a reduction in DHT levels but no visible improvement in hair loss. They are considering switching to oral finasteride for potentially better results.
Lichen Planopilaris (LPP), a form of permanent hair loss, which can be mistaken for seborrheic dermatitis and is characterized by scalp itching, burning, redness, and dandruff. Treatment options discussed include steroidal creams, finasteride, minoxidil, and RU58841.
Treating the itch associated with male pattern baldness, which is believed to be caused by DHT. Potential treatments discussed include salt water, finasteride, ketoconazole, and RU58841.
Concerns about the potential systemic effects and safety of PP405 for hair loss, with discussions on its comparison to existing treatments like finasteride and minoxidil. Users express skepticism about untested research chemicals and emphasize the importance of clinical trials to ensure safety and efficacy.
HairClone aims to rejuvenate miniaturizing hair follicles through follicle banking and cell expansion, with treatments potentially available in the UK by 2022. The process involves extracting, storing, and cloning hair follicles, but full regenerative treatments will take many years to develop.
The user experiencing diffuse hair loss is using various treatments including RU58841, finasteride, minoxidil with tretinoin, anti-hair loss shampoo, and microneedling, and is considering adding peptides TB500, BPC157, and GHK-Cu. They have low growth hormone levels and are questioning its impact on hair loss, while another user suggests androgenic alopecia and androgens are likely the main cause of hair loss.
Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.
A user experienced hair loss and texture changes, tried minoxidil and finasteride, and considered antihistamines like Cetirizine for potential histamine issues. They reported improved alertness but continued shedding.
PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.
User used minoxidil 5% topical liquid, HIMS topical finasteride, derma rolling, DHT blocking shampoo, and castor oil with rosemary for hair loss treatment. They experienced significant progress and increased confidence.
A 26-year-old male with high testosterone is experiencing diffuse hair thinning despite using a comprehensive treatment regimen including dutasteride, oral minoxidil, RU58841, ketoconazole shampoo, microneedling, and low-level laser therapy. Suggestions include adjusting dutasteride dosage, monitoring iron levels, and consulting a dermatologist for further evaluation.
Pelage received $120 million for phase 3 of PP405, a potential hair loss treatment, but there is skepticism about its success. Some users believe any improvement over finasteride is a win, while others expect full hair regrowth.